Late-Phase CMV/EBV Reactivation Impact on Stem-Cell Transplant Survival

Figshare hosts a 5-year single-center cohort study analyzing 202 consecutive hematopoietic stem cell transplantations from 2018-2019. The research investigates the late-phase impact of cytomegalovirus and Epstein-Barr virus reactivation on overall and leukemia-free survival using Cox models. It reports 5-year survival rates and hazard ratios from multivariate analysis.

Use Cases

• Model overall survival (OS) and leukemia-free survival (LFS) hazard ratios based on CMV/EBV reactivation status and viral enteritis.
• Analyze 1-, 3-, and 5-year landmark survival outcomes across patient groups defined by isolated CMV or CMV/EBV coreactivation.
• Investigate the association between sustained CMV replication, identified in multivariate analysis, and long-term mortality risk.
• Assess the predictive value of viral enteritis as an independent adverse factor for 1-year leukemia-free survival.

Strengths

• Study includes 202 consecutive first-ever hematopoietic stem cell transplantations.
• Analysis provides specific 5-year survival rates (e.g., 19.4% with coreactivation) and hazard ratios with confidence intervals.
• Data covers a defined 5-year cohort with uniform preemptive therapy and twice-weekly PCR surveillance.

Limitations

• Dataset is very small in scale (17.7 KB), likely containing summary tables rather than raw patient-level data.
• Single-center study design limits generalizability of findings to other institutions or populations.
• Column structure and sample data are unavailable, restricting detailed analytical reuse.

Provenance

Source

Shanshan Li via figshare

Collection Method

Retrospective analysis of consecutive transplantations with uniform preemptive therapy and PCR surveillance.

Time Range

Transplantations performed between 2018 and 2019, with survival analysis up to 5 years.

Freshness

null

Geography

Single-center study, geographic location unknown.